Javascript must be enabled to continue!
Funding for teratology information services: Up, down, and all around
View through CrossRef
AbstractFunding for Teratology Information Services has been an ongoing struggle over the 25 years of its existence. Traditional and novel funding mechanisms have been explored with varying success. The importance of providing teratology risk assessment and counseling to all women of reproductive age is now an established health care objective. Sufficient and stable funding for these services is essential. Birth Defects Research (Part A) 94:660–663, 2012. © 2012 Wiley Periodicals, Inc.
Title: Funding for teratology information services: Up, down, and all around
Description:
AbstractFunding for Teratology Information Services has been an ongoing struggle over the 25 years of its existence.
Traditional and novel funding mechanisms have been explored with varying success.
The importance of providing teratology risk assessment and counseling to all women of reproductive age is now an established health care objective.
Sufficient and stable funding for these services is essential.
Birth Defects Research (Part A) 94:660–663, 2012.
© 2012 Wiley Periodicals, Inc.
Related Results
The principles of teratology: Are they still true?
The principles of teratology: Are they still true?
AbstractJames Wilson originally proposed a set of “Principles of Teratology” in 1959, the year before he helped to found the Teratology Society. By 1977, when these Principles were...
The neurobehavioral teratology of retinoids: A 50‐year history
The neurobehavioral teratology of retinoids: A 50‐year history
AbstractThis review of the central nervous system (CNS) and behavioral teratology of the retinoids over the last 50 years is a commemorative retrospective organized by decade to sh...
Funding of activities of state veterinary services of Russian Federation Subjects
Funding of activities of state veterinary services of Russian Federation Subjects
The due performance by the veterinary service of its assigned functions depends largely on the amount of funding provided for different aspects and types of its activities. The pap...
Development and Exploitation of a Fully Human and Modular Organotypic Bone Marrow Niche Model to Study the Role of Stroma-Produced Factors in Human MDS
Development and Exploitation of a Fully Human and Modular Organotypic Bone Marrow Niche Model to Study the Role of Stroma-Produced Factors in Human MDS
Background: Myelodysplastic syndromes (MDS) are a heterogenous group of stem cell driven disorders primarily affecting the elderly and characterized by inefficient production of ma...
Performance-based Institutional Research Funding in Flanders, Belgium
Performance-based Institutional Research Funding in Flanders, Belgium
Research and innovation is one of Flanders’ priorities and over the last three decades its public funding has strongly increased. Universities are key actors in this strategy. They...
Funding models for Open Access digital data repositories
Funding models for Open Access digital data repositories
Purpose
– The purpose of this paper is to examine funding models for Open Access (OA) digital data repositories whose costs are not wholly core funded. Whilst such ...
The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
The Development of a Precision Medicine Platform to Overcome Ibrutinib Resistance in Mantle Cell Lymphoma
Background: While mantle cell lymphoma (MCL) initially responds to frontline therapies, this aggressive B-cell malignancy typically relapses or becomes resistant to treatment. Desp...
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
A Phase 1b, Dose-Finding Study Of Ruxolitinib Plus Panobinostat In Patients With Primary Myelofibrosis (PMF), Post–Polycythemia Vera MF (PPV-MF), Or Post–Essential Thrombocythemia MF (PET-MF): Identification Of The Recommended Phase 2 Dose
Abstract
Background
Myelofibrosis (MF) is a myeloproliferative neoplasm associated with progressive, debilitating symptoms that ...

